Aura Biosciences (AURA) Projected to Post Quarterly Earnings on Monday

Aura Biosciences (NASDAQ:AURA) will likely be releasing its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Aura Biosciences to post earnings of ($0.43) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Aura Biosciences Trading Down 0.5%

NASDAQ:AURA opened at $6.55 on Friday. Aura Biosciences has a 1 year low of $4.34 and a 1 year high of $7.73. The stock has a 50-day moving average price of $5.69 and a two-hundred day moving average price of $5.87. The stock has a market cap of $415.93 million, a price-to-earnings ratio of -3.38 and a beta of 0.45.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, December 29th. Evercore initiated coverage on Aura Biosciences in a research note on Tuesday, November 25th. They set an “outperform” rating for the company. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.50.

Insider Activity at Aura Biosciences

In related news, insider Janet Jill Hopkins sold 20,401 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $5.06, for a total transaction of $103,229.06. Following the completion of the transaction, the insider directly owned 232,284 shares in the company, valued at approximately $1,175,357.04. This trade represents a 8.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Amy Elazzouzi sold 8,549 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total value of $43,257.94. Following the completion of the sale, the senior vice president owned 75,532 shares in the company, valued at $382,191.92. The trade was a 10.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 123,076 shares of company stock valued at $618,783 over the last ninety days. Company insiders own 6.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd lifted its position in Aura Biosciences by 145.2% during the 4th quarter. XTX Topco Ltd now owns 60,811 shares of the company’s stock worth $331,000 after buying an additional 36,006 shares in the last quarter. Jane Street Group LLC increased its position in shares of Aura Biosciences by 43.3% in the fourth quarter. Jane Street Group LLC now owns 47,431 shares of the company’s stock valued at $258,000 after acquiring an additional 14,327 shares during the last quarter. Bank of America Corp DE raised its holdings in Aura Biosciences by 41.2% during the third quarter. Bank of America Corp DE now owns 36,183 shares of the company’s stock worth $224,000 after acquiring an additional 10,550 shares in the last quarter. Gallagher Fiduciary Advisors LLC acquired a new position in Aura Biosciences during the second quarter valued at approximately $189,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Aura Biosciences in the third quarter valued at approximately $157,000. Institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.